Eduardo Gómez Castañeda (Eduardo Gómez-Castañeda, Eduardo Gomez-Castaneda)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Chronic Myeloid Leukemia

Helicobacter Pylori

Tyrosine Kinase

Top Venues

University College London Institute of Child Health

University of Glasgow (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University College London Institute of Child Health Aug 01 2019

United Kingdom

Research associate

Perspectum Diagnostics Ltd Mar 25 2019 - Jul 31 2019

United Kingdom

Biomarkers Scientist :: Innovation

Education History

University of Glasgow Oct 01 2014 - Jan 04 2019

United Kingdom

PHD :: Paul O'Gorman Leukaemia Research Centre

Publications

Ilaria M Michelozzi, Eduardo Gómez Castañeda, Ruben V C Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall-Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A Pule, Christopher J Tape, Sergi Castellano, Persis Jal Amrolia, Alice Giustacchini
Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. Blood advances (2022)
Eduardo Gómez Castañeda, Lisa E M Hopcroft, Simon Rogers, Chinmay Munje, Joana Bittencourt-Silvestre, Mhairi Copland, David Vetrie, Tessa Holyoake, Heather G Jørgensen
Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy. Cancers 14 (21) (2022)
Ross Kinstrie, Gillian A Horne, Heather Morrison, David Irvine, Chinmay Munje, Eduardo Gómez Castañeda, Hothri A Moka, Karen M Dunn, Jennifer E Cassels, Narissa Parry, Cassie J Clarke, Mary T Scott, Richard E Clark, Tessa L Holyoake, Helen Wheadon, Mhairi Copland
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia 34 (6) (2020)